Tag: FDA

McGill bioethicists argue for stricter limits on first-in-human clinical trials

The standards for drugs entering first-in-human (FIH) clinical trials are too low, argues Associate Professor Dr. Jonathan Kimmelman and PhD candidate Carole Federico in McGill’s Biomedical Ethics Unit. In a commentary published online in Nature on Jan. 30, Kimmelman and Federico maintain that evidence for drug efficacy is not emphasized enough before[Read More…]

Drug price hike causes global outrage

Martin Shkreli, CEO of Turing Pharmaceuticals, was harshly criticized last week after raising the cost of one of the company’s drugs, Daraprim, from $13.40 USD to $750 USD—an increase of 5,000 per cent. Manufactured exclusively by Turing, this price hike has reignited the debate on the ethics of charging patients for[Read More…]

Read the latest issue